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Abstract
We propose the hypothesis that loss of estrogen receptor function which leads to endocrine resistance in breast cancer, also
results in trans-differentiation from an epithelial to a mesenchymal phenotype that is responsible for increased
aggressiveness and metastatic propensity. siRNA mediated silencing of the estrogen receptor in MCF7 breast cancer cells
resulted in estrogen/tamoxifen resistant cells (pII) with altered morphology, increased motility with rearrangement and
switch from a keratin/actin to a vimentin based cytoskeleton, and ability to invade simulated components of the
extracellular matrix. Phenotypic profiling using an Affymetrix Human Genome U133 plus 2.0 GeneChip indicated geometric
fold changes $3 in approximately 2500 identifiable unique sequences, with about 1270 of these being up-regulated in pII
cells. Changes were associated with genes whose products are involved in cell motility, loss of cellular adhesion and
interaction with the extracellular matrix. Selective analysis of the data also showed a shift from luminal to basal cell markers
and increased expression of a wide spectrum of genes normally associated with mesenchymal characteristics, with
consequent loss of epithelial specific markers. Over-expression of several peptide growth factors and their receptors are
indicative of an increased contribution to the higher proliferative rates of pII cells as well as aiding their potential for
metastatic activity. Signalling molecules that have been identified as key transcriptional drivers of epithelial to mesenchymal
transition were also found to be elevated in pII cells. These data support our hypothesis that induced loss of estrogen
receptor in previously estrogen/antiestrogen sensitive cells is a trigger for the concomitant loss of endocrine dependence
and onset of a series of possibly parallel events that changes the cell from an epithelial to a mesenchymal type. Inhibition of
this transition through targeting of specific mediators may offer a useful supplementary strategy to circumvent the effects
of loss of endocrine sensitivity.
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Introduction
Frequent and unpredictable onset of an endocrine drug
resistant phenotype continues to pose significant problems for
long term management of breast cancer patients [1,2]. Variously
derived models of antiestrogen resistant cells have failed to
highlight any single mechanism entirely responsible for this
phenomenon [3]. Over-expression of tyrosine kinase receptors
(RTKs) for a variety of other cellular mediators of proliferation
has been frequently reported [3–5]. Convergence at downstream
elements such as MAPK, pI3K, SRC and AKT (all gene symbols
used in this report follow approved nomenclature as defined in
the HUGO database; http://www.genenames.org/index.html)
has been implicated in situations where the classical route via
genomic estrogen response elements has become redundant. Bi-
directional crosstalk between ER and RTK mediated signalling is
implicated as a major route to endocrine resistance [6] with
identification of several potential contributing factors including
GATA3, GATA4, FOXp3, pAX2, NCOA3 and SRC members
[7–9]. Endocrine resistance is generally characterised by
accelerated growth and increased aggressive behaviour, and
associated with morphological changes characteristic of cells
undergoing epithelial-to-mesenchymal transition (EMT) [10].
Epithelial carcinoma cells may acquire a mesenchymal-like state
to facilitate migration and invasion and undergo reversion
(mesenchymal to epithelial transition; MET) to form organized
tumourigenic nodules at lodgement sites. During EMT and
MET, a bimodal communication exists between the host
fibroblasts, extracellular matrix/basement membrane and the
immune cells that involves a series of transcriptional re-
programming steps requiring participation of several transcrip-
tion factors including ZEB1/TCF8, SNAIL1, ZEB2, SNAIL2,
E12/E47, FOXC2, GOOSECOID, and TWIST [11,12]. A
defining feature of EMT is the loss of the homotypic cell adhesion
molecule E-cadherin (CDH1) and the occludins [13,14] which
together with claudins and tight junction proteins are integral
components of adherens junctions forming the cohesive archi-
tecture of normal epithelia. This is very likely an initiating step for
transition of breast tumours from a benign to an invasive state
[15–17], leading to vascular metastasis [18–20]. Expression of the
E-cadherin repressor proteins, SNAIL, TWIST, ZEB1 (EF1),
LCN2 and KLF8 is increased in EMT, with concurrent loss of
cytokeratins such as CK8, 18, and 19 and the appearance of N-
cadherin (CDH12) and/or cadherin-11 [13,14,21] and most
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that is over-expressed in breast carcinomas undergoing EMT and
exhibiting increased cell migration and invasion [10,22]. It is co-
ordinately regulated together with other mesenchymal markers,
such as the extracellular matrix molecule tenascin C [23], whose
expression in human breast carcinomas correlates positively with
ERBB2 over-expression and down-regulation of ER. Vimentin,
along with fibronectin (FN1), is up-regulated by LCN2 [24] in
contrast to E-cadherin and cytokeratins, Another EMT marker is
AXL, which is a member of the TAM (TYRO-AXL-MER)
receptor tyrosine kinases that share the vitamin K-dependent
ligand growth arrest-specific gene 6 [21]. TAM family RTKs
regulate a diverse range of cellular responses including cell
survival, proliferation, autophagy, migration, angiogenesis, plate-
let aggregation, and natural killer cell differentiation [25]. HOX
genes are also associated with tumour progression and have been
implicated in many types of cancers including lung, prostate,
ovarian, and endometrial cancer. Over-expression of HOXB7 in
SKBR3 breast cancer cells was found to directly or indirectly
regulate the expression of many angiogenic and growth factors,
including bFGF, VEGF, interleukin 8, ANG1 and 2, and matrix
metalloproteinase (MMP) 9, and resulted in formation of well-
vascularized tumours when grown as xenografts in nude mice
[26,27]. HOXB9 has a similar effect leading to increased cell
motility and acquisition of mesenchymal phenotypes [28].
Another mesenchymal/EMT marker is FSP1/S100A4 that has
provided in vivo evidence implicating EMT in onset of metastasis
[13], facilitated through activation of MMP9 and SPARC [14]. A
family of more than 28 members, MMPs are up-regulated in
nearly every tumour type and are intimately involved in cancer
progression through cleavage and release of bioactive molecules
that inhibit apoptosis and stimulate invasion, as well as through
degradation of extracellular matrix (ECM) components that
promote tumour cell growth [29].
In a recently established cellular model of endocrine resistance
[30], we provided preliminary evidence suggesting that loss of ER
function can result in trans-differentiation of the epithelial
phenotype. There is already sporadic evidence, in the literature,
of the association of some characteristics of EMT with ER status,
particularly in the case of vimentin [31]. Several studies have
examined gene expression profiles of ER+ve and ER-ve breast
cancers [32] and performed microarray analyses on breast tissues
in an attempt to sub-classify patients on the basis of their global
pattern of gene expression [33–36]. Recently, expression profiling
has been used to demonstrate a link between drug resistance and
the adoption of an EMT phenotype in MCF7 cells [37].
Surprisingly however, phenotypic and transcriptome alterations
in breast cancer cells secondary to ER silencing have hardly been
explored. In this report we present data to show that induced loss
of ER directly results in the development of EMT and provides a
link between this process and endocrine resistance.
Methods
Cell lines
MCF7 and MDA231 human breast carcinoma cell lines,
derived from the ATCC (American Type Culture Collection,
VA, USA) were maintained at 37uC in a humidified atmosphere
of 5% CO2 in DMEM supplemented with 10% foetal bovine
serum (FBS), 600 mg/ml L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin and 6 ml/500 ml 100 x non-essential
amino acids (Invitrogen, CA, USA). Endocrine independent cell
line pII was established by transfection of MCF7 with ER
directed shRNA plasmid as described previously [30,38]. Another
transfected cell line designated E2 was established that had
retained sensitivity to estrogen and tamoxifen (presumably as a
result of failure to produce siRNA) and was used as an additional
control.
Transfections
Complementary oligos (synthesised by Eurogentec, Belgium)
containing an ER directed shRNA sequence 59GCTTCAGGC-
TACCATTATGttcaagagacataATGGTAGCCTGAAGCttttttac-
gcgt-39 (ER sense and anti-sense shown in uppercase and
intervening loop sequence and transcription termination se-
quences shown in lower case) were hybridised, purified and
cloned into the Hind III/ Xho1 site of pSingle-tTS vector
following the manufacturer’s cloning protocol (Clontech, UK).
Standard CaCl2 transformation into DH5a E coli was followed
by plasmid isolation and purification using Qiagen mini kits
(Qiagen, CA, USA). Transfection into MCF7 was performed
using TransFast reagent (Promega, Southampton, UK) as per
the manufacturer’s protocol. Cell lines SY1.2 and SY2.5 were
established from two G418 (1 mg/ml) resistant clones.
Cell proliferation
Various numbers of cells from 10
4–6.10
4 were seeded into
triplicate wells of 12-well plates and growth assessed over 4–6 days,
following trypsinisation and resuspension in medium, by direct cell
counting using a haematocytometer.
Cell motility assay
Cells were grown to 80–90% confluency in 12 well plates. A
scratch was made with a yellow eppendorf tip through the center
of the monolayer. Detached cells were removed by gentle washing
with PBS and fresh medium added. The width of the scratch was
monitored by light microscopy after 24 and 48 h to determine the
extent if any of cell migration into the scratched space.
Phalloidin staining
Exponentially growing cells were washed with PBS, fixed for
5 min in 3.7% formaldehyde/PBS, washed in PBS, dehydrated
with acetone and permeabilised with 0.1% Triton X-100 in PBS.
After a further wash with PBS, cells were stained with phalloidin
conjugate solution (50 mg/ml) in PBS containing 1% DMSO for
40 min, at room temperature. Unbound conjugate was removed
by several washes with PBS before histological visualisation and
photography using LSM 510 META confocal microscope (Carl
Zeiss, Germany).
Invasion through basement membrane extract
This assay was performed using 24-well cell invasion chambers
from Trevigen (MD, USA) according to the manufacturer’s
instructions. Plates were equilibrated for 1 h at room temperature.
Inserts were rehydrated by addition of 100 ml of warm (37uC) 1 x
Rehydration Solution and incubated at 37uC for 1 h. Trypsinised
pelleted cells were rinsed with wash buffer and re-suspended at
10
6 cells/ml in serum free medium. Cells (100 ml) were added to
the top chamber of each well. After incubation, the top chambers
were aspirated and washed with 100 ml of warm wash buffer. The
bottom chambers were also aspirated and washed twice with
500 ml wash buffer. Calcein AM solution (500 ml) was added to the
bottom chambers and the unit re-assembled, followed by
incubation at 37uC for 1 h. Chambers were disassembled and
the plates read in a Fluroskan Ascent plate reader (Thermo-
Electron Corporation, USA) at 520 nm emission with 485 nm
excitation The number of cells migrating through the matrix was
Breast Cancer: Epithelial-Mesenchymal Transition
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numbers of pII cells.
Agarose spot invasion assay
One or more agarose spots were made by pipetting 10 mlo f
sterile 0.5% molten low melting agarose (prepared in isotonic PBS)
into wells of a 12-well plate and allowing to solidify for several
minutes at 4uC. About 10
4–10
5 cells re-suspended in 1 ml DMEM
were then pipetted into each well and left at 37uC for 24–48 h.
During this time plates were periodically examined to monitor the
penetration of cells into the agarose spot.
Realtime quantitative PCR
Total cellular RNA was extracted from frozen cell pellets using
the RNeasy kit (Qiagen, USA) according to the manufacturer’s
protocol, and 2 mg (in 20 ml) converted to cDNA using a high
capacity cDNA reverse transcriptase kit (Applied Biosystems, CA,
USA). Quantitative realtime PCR was performed on 1 ml cDNA
using a standard multiplexed TaqMan PCR kit protocol
[manufacturer proprietary primer/probe mixes: FAM/TAMRA
labelled target was combined with Joe labelled normaliser actin
gene] to determine expression of ER, keratin 19, E-cadherin, N-
cadherin, fibronectin, vimentin, plasminogen activator-urokinase
(PLAU) and CD68 and actin. The 20 ml reactions were performed
in a 96-well plate on an Applied Biosystems 7500HT Sequence
Detection System by incubation at 95uC for 10 min, followed by
40 cycles of 95uC for 15 s and 60uC for 1 min. The raw threshold
cycle (CT) values were analysed by the DDCt method using the
spreadsheet developed by Pfaffl [39] to determine normalized
expression ratios of target genes.
Microarray analysis
High quality RNA prepared from MCF7 and pII cells with
array grade RNA extraction kit from SABiosciences (MD, USA)
was converted to cDNA using the Affymetrix One-Cycle cDNA
Synthesis Kit (Affymetrix Technologies, CA, USA). In vitro
transcription and hybridization in triplicate for each cell line onto
Affymetrix Human Genome U133 plus 2.0 GeneChips were
performed as previously described [40]. All samples passed the
Affymetrix quality control algorithm. The Cel files from each
sample were exported to Partek Genomics Suite V 6.5 for RMA
background correction, quantile normalisation with GC content
adjustment (Partek Incorporated, St Louis, Missouri). ANOVA p
value for differentially expressed genes was set to 0.05 or less. Gene
Ontology (GO) Enrichment Analysis and Visualization tool
(Gorilla) was used to determine Gene Ontology categories
(http://cbl-gorilla.cs.technion.ac.il/). Functional analysis was per-
formed on the entire data set with the Ingenuity Pathways Analysis
Figure 1. Morphology and growth rates of MCF7 and pII cells. Panels A and B: Phase-contrast optical photomicrographs of single colonies of
MCF7 and pII respectively. Scale bar represents 100 mm. Panel C: Cell shape analysis was performed using an ImageJ freeware package; histograms
show mean cell parameter 6 SEM of 4 independent determinations quantifying morphological differences between MCF7 and pII cells (p , 0.04).
Panel D: Equivalent numbers of MCF7 and pII cells (10
4) were seeded into 12-well plates and grown over 6 days. Cells were harvested from triplicate
wells on the days indicated and growth determined by cell counting. Differences at days 4, 5 and 6 were significant with p#0.0001.
doi:10.1371/journal.pone.0020610.g001
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This programme works by mapping the average gene expression
of transcripts to hypothetical networks available in the Ingenuity
database and ranks them by a score that indicates the likelihood of
the genes in a network being found together due to random
chance. In addition, the data was mined for genes with specific
functional relevance to endocrine function, metastasis and EMT
by manual selection. All the Affymetrix raw data is MIAME
compliant and has been deposited in a MIAME compliant
database GEO, as detailed on the website: http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE27473.
Statistical analyses
Means of experimental groups were compared with those of
other experimental groups or controls using the student’s t-test.
Statistical significance was assumed at p values #0.05.
Results
Cell morphology and proliferation
MCF7 cells typically grow as closely packed colonies forming
sheet–like monolayer structures upon achieving confluency. In
contrast, pII cells showed distinct morphological differences under
the same growth conditions, as illustrated in Fig. 1, assuming a
generally smaller more variable elongated and spindle or sometimes
round shape, growing near to each other but forming loosely
associated colonies of cells even at high density. Figure 1 panel C
shows a quantitative analysis of the size/shape parameters of the
two cell lines using ImageJ software. Time lapse photography
showed that pII cells assumed a roundish appearance prior to cell
division and then separated from each other whereas MCF7 cells
remained together (data not shown). pII exhibited about 50% faster
growth rates than MCF7 (Fig. 1D).
Figure 2. Motility assay of MCF7, pII and MDA231. Cells were
plated into individual wells of a 6 well microwell dish and allowed to
grow to ,80% confluency. A scratch was made across the centre of the
cell monolayer with a yellow eppendorf pipette tip (as shown in
cartoon) creating a parallel space. Damaged cells were removed by
carefully aspirating off the medium and rinsing with PBS before
addition of fresh medium containing 2% serum. Upper panels show
comparative microscopic view of MCF7 (a–b) and pII (c–d) cells in the
scratched area at 0 time (a, c) and after 24 h [b, d] for a typical
experiment. Chart shows the combined quantitated results from 3
independent experiments for the cell lines indicated. Histobars
represent the mean [6 standard deviation] width of the original
scratch space at 0, 24 and 48 h. Wound closure indicates movement of
cells into the scratch. *Significantly different from MCF7 cells at
respective times with p#0.006.
doi:10.1371/journal.pone.0020610.g002
Figure 3. Confocal laser scanning microscope analysis of
individual MCF7 (A) and pII (B) cells showing differences in
both intensity and arrangement of F actin filaments visualised
by phalloidin staining as described in Methods. Microspikes and
lamellipodia-like structures are visible in the pII cells. Both photographs
were enhanced equally by auto-contrast in Adobe Photoshop. Scale bar
indicates 10 mm.
doi:10.1371/journal.pone.0020610.g003
Figure 4. Invasion assay of MCF7, E2, pII and MDA231 cells
through simulated ECM protein components. Cells were plated
into the upper chambers of the cell invasion plate and incubated for
48 h prior to measurement of the fluorescence intensity of the invading
cells in the bottom chambers. MCF7 and E2 cells were considered non-
invasive (,20 FU/m), whereas pII and MDA231 cells progressively
invaded the BME (.100 FU/m). Histobars represent the mean 6 SEM of
at least 3 independent determinations of the fluorescent intensity of
the invading cells in the bottom chamber. This experiment was
performed three times with similar outcome. pII and MDA231
significantly different from MCF7 with p,0.0001.
doi:10.1371/journal.pone.0020610.g004
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A pre-requisite for tumour cells to become invasive is loss of cell-
cell adhesion to allow them to become more motile. We tested the
ability of MCF7 and pII cells to move into a space created through
an approximately 80% confluent monolayer as described in
Methods. Although movement of some cells into the space could
be seen after about 8 h accurate measurements could only be
recorded from about 24 h. Observations made at longer periods
do introduce additional complication that proliferation of cells that
have moved into the scratch could contribute to the total number
of cells seen within the scratch. The use of low serum in the
medium is likely to minimise this effect, but at the same time it
does reduce the movement of the cells to some extent, compared
to normal serum conditions (data not shown). Another option
sometimes employed is to use a mitotic inhibitor such as
mitomycin C but this was not done in case this also affected
motility. These considerations aside, we noted a significant
reduction in the width of the scratch for pII as compared to both
MCF7 and E2 cells indicating that pII cells had moved laterally
into the space to a far greater extent. The change in the width of
the scratched region from 0 to 24 and 48 h is displayed in Fig. 2.
The ER -ve MDA231 cells behaved similarly to the pII, moving
into the scratched space.
Distribution of the actin cytoskeleton
Following staining with phalloidin, pII cells exhibited an
extensive and complex array of F-actin-rich structures that may
represent lamellipodia and microspikes at the cell periphery, a
phenomenon generally referred to as membrane ruffling. On the
other hand, MCF7 cells showed a more regular distribution of F-
actin filaments throughout the cells with no extensive membrane
ruffling (Fig. 3).
Cell invasion
Invasion of cancer cells through the basement membrane into
the extracellular matrix (ECM) is an essential step in cancer
Figure 5. Agarose spot assay. Panel A is a cartoon to illustrate
agarose spot inside well with cells added some of which settle around
the periphery. MCF7 (B) and pII (C, D) cells were plated into individual
wells of a 12 well dish containing an agarose spot, and photographed
after 24 h of incubation. MCF7 cannot penetrate even at high density
whereas pII do so even at very low density (D). Arrows delineate the
periphery of the agarose spot beneath. Scale bar represents 400 mm.
This experiment was repeated at least ten times with identical outcome.
The numbers of pII cells entering the agarose varied with density of
cells settling at the periphery, and time.
doi:10.1371/journal.pone.0020610.g005
Figure 6. Biological processes affected by ER silencing. GO terms most significantly affected or disrupted secondary to ER silencing. Each GO
term is boxed in a rectangle and shaded according to the p value as indicated. Enrichment (N, B, n, b), where indicated is defined as (b/n)/(B/N), where
N - is the total number of genes, B - is total number of genes associated with a specific GO term (‘target’ set and ‘background set’), n - is number of
genes in the ‘target set’, b - is number of genes in the ‘target set’ associated with a specific GO term.
doi:10.1371/journal.pone.0020610.g006
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ability to pass through the BME, indicated by fluorescent signals
from the invading cell population in the bottom chamber of the
cell invasion plate. In comparison, the fluorescent signal from the
medium in the lower chamber for MCF7 was very low indicating
that these cells were limited in their ability to penetrate through
the BME (Fig. 4). Polysaccharides also constitute a major
structural part of the ECM. Therefore we assessed the ability of
the cells to invade through this component using the agarose spot
assay described by Wiggins and Rappoport [41]. MCF7 cells were
seen to accumulate at the agarose junction but did not enter the
agarose. Even after 72 h when the cells were extremely confluent,
they simply piled up against the agarose and were clearly unable to
enter it. In sharp contrast, the pII cells were seen to penetrate into
the agarose spot and accumulate in increasing numbers as time
progressed, as illustrated in Fig. 5. These movements were
observed irrespective of whether there was high or low initial
density of pII cells at the agarose periphery.
Transcriptome profiling
EMT and related therapeutic resistance are complex biological
processes, likely to involve participation of many genes, and may
be addressed by the use of an unbiased method such as
microarray. To that end, we utilized the Affymetrix GeneChips
in an attempt to decipher transcriptomic alteration secondary to
ER silencing. GO analysis has emerged as a powerful tool aimed
at organizing gene expression data into a meaningful output
associated with biological processes [42]. Using Anova p value set
at ,10
26 as the representative for the ranked and differentially
expressed genes between MCF-7 and pII cells, nine GO terms
emerged as the most significant biological processes disregulated
upon ER silencing (Fig. 6). Consistent with higher growth rate and
the altered morphology seen in pII cells, anatomical structure
morphogenesis (GO:0009653), regulation of cell proliferation
(GO:0042127) and cellular adhesion (GO:0022610 and
GO:0007155), were among the most significant GO terms altered
after silencing ER. Moreover, Fig. 7 shows that the majority of
deregulated genes coded for plasma membrane associated or
extra-cellular proteins (GO:0005886 and GO:0005576 respective-
ly). The complete gene lists and analyses have been submitted (to
geo@ncbi.nlm.nih.gov, url: ) and will be available on Gene
Expression Omnibus website (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE27473).
To look specifically at deregulated intracellular signalling
pathways, we searched the entire unselected dataset using the
Ingenuity Pathway Analysis (IPA) programme with specific
reference to pathways associated with metastasis and invasion.
We found that a number of changes had occurred in gene
networks whose products have been implicated in cell to cell
interactions and in cell motility. The majority of genes currently
known to be involved in cellular interactions particularly those
with functions associated with the extracellular space were up-
regulated in pII cells (Fig. S1). The behaviour of genes involved in
cell movement and adhesion was even more striking (Fig. S2), with
all but two identified genes being up-regulated in pII. For more
focussed analysis, a reductive process was used to restrict the data
by imposing an arbitrary cut-off level of significance (p,10
25) and
limiting consideration to sequences exhibiting geometric fold
changes $3 and excluding those with no specific structural or
Figure 7. Cellular components affected by ER silencing. See legend to Figure 6.
doi:10.1371/journal.pone.0020610.g007
Table 1. Peptide growth factor/receptor genes associated
with endocrine resistance.
Up regulated in pII Down regulated in pII
FGFR1, FGF1,5,13, EGFR, TGFa FGFR2, 3, 4, FGF12, TGFb3
TGFb1, 2, TGFbR1, 2, 3 ERBB2, ERBB3, ERBB4
PDGFA, PDGFC, PDGFD
VEGFA, VEGFC, HBEGF, CTGF
doi:10.1371/journal.pone.0020610.t001
Table 2. Luminal and basal markers.
Luminal markers* GATA3, XBP1, PRLR, MAPT, TIFF1, 3
Basal Markers
+ EGFR, LYN, CAV1,2, MSN, ETS1, CD44,5
AnnexinA1, WNT 5A, 5B, LAMC2
*downregulated in pII, +upregulated in pII.
doi:10.1371/journal.pone.0020610.t002
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somal location. This left 2500 identifiable unique sequence
differences between MCF7 and pII mRNA. Of these, approxi-
mately 1270 genes were comparatively up-regulated and the
remainder down-regulated in pII. The ER regulated genes, PGR,
CATHD and TFF1 and TFF3 as well as PRLR were predictably
reduced. Amongst growth factors and their receptors, differences
were observed between family members with the majority being
higher in pII (Table 1). We also noted a clear distinction in
expression of luminal and basal cell markers that have been
identified as such in breast tumours [35] with the latter being
consistently higher in pII (Table 2). We also looked for genes
reported to be associated with invasion and metastasis (Table 3).
Typical examples of pII up-regulated genes included vimentin and
N-cadherin, fibronectin and tenascin C, WNT3, WNT5A and
WNT5B, SMAD 3 and 4 and signalling molecules such as AKT
and ZEB1, with concurrent decrease in E-cadherin, SMAD 1 and
6, keratin 7 and HOX genes. When we examined genes that have
been designated as either epithelial or mesenchymal specific,
almost without exception, all epithelial markers were down-
regulated and mesenchymal markers up-regulated in pII (Table 4).
A number of signalling molecules have been identified as key
transcriptional drivers of EMT. Of these, SNAIL1 and 3, TWIST,
ELK3 and TCF4 were unaltered whereas SNAIL2 (SLUG), ZEB
1 and ZEB2/SIP were higher in pII and TCF3/ E47/E12, and
ELF3 were lower. The ER induced inhibitor of SNAIL1, MTA3,
and GATA3, which inhibits breast cancer metastasis through the
reversal of EMT [9], were also significantly lower.
Gene expression analysis by realtime PCR
To validate the microarray data, relative levels of 12 randomly
selected genes in the MCF7 and pII derived cDNA preparations
were measured by realtime Taqman PCR amplification [data not
shown]; in all cases the results correlated precisely. Amplifications
were also performed with a further 8 genes; ER, keratin 19, E-
cadherin, N-cadherin, fibronectin, vimentin, CD68 and PLAU for
MCF7, pII and MDA231 cells (Fig. S3) confirming a clear division
between epithelial and mesenchymal marker expression. Whereas
MCF7 showed high expression of ER, keratin 19 and E-cadherin,
the others were all greatly reduced. The reverse was observed for
both pII and MDA231 cells.
Timescale of EMT
The data presented here was obtained with pII cells that had
been passaged in excess of 15 times following initial cloning. To
determine how quickly after ER silencing the changes actually
occurred, new transfections of MCF7 cells were performed using
ER targeting shRNA cloned into pSingle-pTs vector and two
adjacently growing transformants that displayed morphology
similar to MCF7 and pII (Fig. 8 inset) were cloned and examined
within 3 passages of selection. Expression of the gene set described
previously was assessed by realtime PCR. The data in Fig. 8 shows
that the MCF7-like clone had failed to down-regulate ER and
exhibited a profile similar to the parental line whereas the one
resembling pII exhibited almost complete loss of ER and
developed the ‘EMT signature’ pattern.
Discussion
In this study we show that ER+ve MCF7 breast cancer cells that
have undergone enforced long term ER deprivation by siRNA
silencing (pII cell line), and acquired an endocrine resistant state
[30] with loss of estrogen regulated gene expression, display a new
phenotype that has features distinctly reminiscent of mesenchymal
cells. They have a faster growth rate, changed morphological
appearance with loss of intercellular adhesion and cytoskeletal
redistribution that promotes increased locomotive activity and
interaction with the ECM. Elevated CAPG is consistent with loss
of aggregation, invasion and motility observed with its down-
regulation in ER-ve MDA231 cells [43]. Ingenuity Pathway
Analysis of the Affymetrix screen data showed increased
expression of many genes whose products are involved in cell
motility and in cell-cell interactions located both within the
cytoplasm and also extracellularly (Figs. S1 and S2) indicating the
Table 3. Genes associated with invasion and metastasis.
Up-regulated in pII Down-regulated in pII
CDH12, FN1, TNC CDH1,3, F11R, DSC2, DSP
WNT3, 5A,5B, JAG1, CAV1,2. SMAD 3,4 NOTCH3, SMAD 1,6
CALB2, ZEB1, EREG,TMEFF1, UGT8 MAN1A1, CLN8, TFF1
KRT7, NEDD9
AKT2,3, CNK1, AXL, MSN, MAP1B
PLEK2, MAP4
VIM, CXCL1, TIMPs 1,2,3,4, SERPINE1 CXCR4, LY6E, BMP7
COX2, SAT, CALD1, RGS2, CAPG HOX, HIST1H4
doi:10.1371/journal.pone.0020610.t003
Table 4. Epithelial and mesenchymal markers.
Functional class *Epithelial markers
+Mesenchymal
markers
Membrane glycosylated
phosphoprotein
MUC1 MUC15
Matrix metalloproteinases MMPs9,15,17,24 MMPs1,14
Cell cycle molecules Cyclin M1, M4 CyclinsA1, D2, E2
Membrane proteins CD24, 42 CD44,59,68,73,99
Cytoskeleton proteins Keratin 7,8,15,18, 19 VIM
Adhesion molecules CDH
1,3,5,9,10,11,13,14,16,19
CDH4,8, 11, 12
Protocadherins1,5,8–
10,13,14,16,19
Pro-cadherin 7,18,20
Annexin A9, Catenin,
ICAM3
Annexin A1, ICAM1,2
CLDN3,4,23 DSP, OCLN,
TJP3
NCAM2, LOXL2
GJB3, JPH3, JUP, SELL Integrin a3, b1
FN1,FLNC
Collagen family Col 4A1,5A1,6A1,7A1
12A1,13A1,4A5
4A6,4A2,6A2,9A2
Transcription factors GATA3, XBP1
Heat shock protein HSP90AA1 HSPA1A
Matrix associated protein SPARC
Membrane receptors PRLR
Secretory molecules EDN1
Other PLAU, PLAUR, SMA
*Downregulated in pII,
+upregulated in pII.
doi:10.1371/journal.pone.0020610.t004
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penetrate simulated components of the ECM similarly to
MDA231 (described as a mesenchymal cell; [35]) that are not
operative in MCF7. pII resemble basal-like metaplastic and
claudin/occludin-low tumour subtypes, with loss of luminal cell
markers (Table 2), that have the propensity for inter-cellular
detachment by ‘cadherin switching’ [13,44] from E-cadherin to N-
cadherin, degradation of the basement membrane through the
action of various metalloproteinases and molecules listed in Table 3
and establishment of connections with elevated collagen compo-
nents of the ECM in order to crawl into and through it into the
vasculature. Cancers undergoing EMT display cell intermediate
filament status changes from a keratin rich network connected to
adherens junctions and hemidesmosomes to a vimentin base
connecting a focal adhesion [22]. Vimentin is expressed at sites of
elongation suggesting its putative role in facilitating migration as
demonstrated with pII cells. Its expression also correlates with cell
migration, invasion and EMT induction in several breast cancer
cell lines in association with other mesenchymal markers such as
fibronectin and tenascin C [10,31] both of which were highly up-
regulated in pII, with accompanying loss of cytokeratins and the
classic epithelial marker, MUC1. Over-expressed basal markers
CAV 1 and 2 are key molecules for cell migration involved in
plasma membrane dynamics and cellular trafficking [45].
Mitogenic signals through EGFR [46], IGFR [47] and FGFR1
[48] are implicated in tamoxifen resistance and correlated with
invasiveness. We observed increased expression of EGFR, FGFR1
and TGFbR1, 2 and 3 as well as several growth factor ligands
including TGFa, TGFb and several FGFs, PDGFs and VEGFs as
well as WNT genes (Table 1) that control signalling through the
RAS, SRC, PI3K and SMAD pathways, which are all implicated
in EMT. TGFb1 binding to heterodimeric complexes of TGFbR1
and 2 can mediate phosphorylation of SMAD 2 and 3 which in
conjunction with SMAD 4 translocates to promoters such as SP1
that regulates SNAIL1 [49,50] and interacts with other transcrip-
tion factors, co-activators and co-repressors to suppress epithelial
genes and promote expression of mesenchymal proteins [51].
Non-SMAD signaling through activation of ERK MAPK, RHO
GTPases, and PI3K/AKT has also been implicated in TGF-beta-
induced EMT [52]. Annexin A1 can also increase cell scattering
and SMAD 3/4 transcriptional reporter activity and actin
reorganization, which facilitates an EMT-like switch [53].
pII have high expression of other transcriptional repressors of E-
cadherin [17] that include SNAIL2, ZEB1 and ZEB2/SIP, which
also indirectly promotes vimentin expression [54] as well as
GOOSECOID and FOXC2 [55,56]. Another up-regulated
marker is CD44, a b-catenin/TCF/LEF-1 target and a cell
surface adhesion molecule involved in cell-cell and cell-matrix
interactions, in association with simultaneous CD24 down-
regulation. Tumours with a CD44+/CD24- phenotype are highly
invasive [57] with targeted reduction of CD44 markedly reducing
malignant characteristics of tumours in vivo. MSN anchors CD44
and is included in a gene expression signature associated with cell
motility and invasion [35].
MTA3 is a subunit of the Mi-2/NuRD histone deacetylase
complex [58] which is a key component of an ER dependent
pathway that is responsible for the suppression of SNAIL. The loss
of ER function and hence decreased MTA3 in pII cells would lead
to de-repression of SNAIL transcription, cadherin switching and
progression towards EMT. Immunoreactivity for MTA3 also
correlated with ER-ve status of breast tumours and lack of E-
cadherin. Depletion of MTA3 does not however appear to affect
SNAIL2 which in contrast to SNAIL was over-expressed in pII. It is
therefore not clear to what extent the loss of MTA3 contributes to
EMT in these cells. Interestingly, ligand-activated ER can mediate
transcriptional repression of SNAIL2; an effect that could be
reversed by ER silencing in MCF7 [59]. Moreover, Hugo and
colleagues [60] conclude in a review on the role of EMT in cancer
progression that thereis more evidencetosupport a role forTWIST
and SNAIL2 in the mesenchymal phenotype than SNAIL 1.
All of our data are consistent with the observation that loss of
ER in MCF7 cells drives them towards EMT. The pII cells have
acquired characteristics very similar to those exhibited by the
MDA231 cells that were originally isolated from a de novo ER –ve
tumour. The key players that have been identified as either
promoted or suppressed during EMT are frequently similar to
those described for endocrine resistant cells. It is also clear that a
large number of diverse signalling pathways are involved in both
processes. Their relative importance remains to be determined, as
does the temporal sequence of events. Our initial notion that loss
Figure 8. Realtime PCR analysis of epithelial and mesenchymal
markers in MCF7, YS1.2 and YS2.5 cells. Extracted RNA was
converted to cDNA and amplified using the Taqman procedure as
described in Methods. Histograms represent means of duplicate
determinations. Similar results were obtained in two separate
experiments. Expression was normalized to the level found in MCF7
cells (arbitrarily fixed as 100), with b actin used as an internal control.
Photomicrograph shows the morphology of the two original adjacent
G418 resistant colonies from which YS1.2 and YS2.5 were cloned. Scale
bar represents 100 mm.
doi:10.1371/journal.pone.0020610.g008
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independent phenotype, as appears to be the case with most
endocrine resistant cell models described in the literature, led us to
examine these cells only after continuous propagation over many
cell divisions to ensure their stability. That both endocrine
independence and EMT can in fact occur quite rapidly following
ER silencing is indicated very clearly by the preliminary analysis of
the more recent transfectants YS1.2 and YS2.5 that shows
acquisition of our ‘EMT signature’ is actually acquired very soon
after stable selection.
In summary our data point to the conversion of MCF7 cells into
an endocrine resistant state triggered by the functional loss of ER,
which directly and swiftly initiates a complex series of processes
that lead to EMT, resulting in an aggressive re-orientated and
highly metastatic cell. Recognition of the link between these
processes is already leading to exploration of newer intervention
strategies [61] to address the clinical issue of endocrine resistance.
A recent review [62] discusses the growing, often circumstantial
evidence that breast cancer metastasis may be regarded as a
specific form of EMT.
Supporting Information
Figure S1 A molecular interaction node depicted by
Ingenuity Pathway Analysis centered on molecules
involved in cell to cell interaction and subdivided into
cellular component/location. The nodal relationships are
shown by solid lines indicating direct known interactions and
dashed lines for indirect interactions. Additionally, the shape of
each node indicates the molecular class. Red nodes indicate
overexpression in pII cells and green nodes underexpressed
transcripts, with un-coloured nodes as unaltered expression.
(TIF)
Figure S2 A molecular interaction node depicted by
Ingenuity Pathway Analysis centered on molecules
involved in cellular motility and subdivided into cellular
component/location. The nodal relationships are shown by
solid lines indicating direct known interactions and dashed lines for
indirect interactions. Additionally, the shape of each node
indicates the molecular class. Red nodes indicate overexpression
in pII cells and green nodes underexpressed transcripts, with
uncoloured nodes as unaltered expression.
(TIF)
Figure S3 Realtime RT-PCR analysis of epithelial [ER,
CDH1, K19] and mesenchymal (PLAU, VIM, CDH12,
CD68, FN1 and VEGF) markers in MCF7, pII and
MDA231 cells. Extracted RNA was converted to cDNA and
amplified using Taqman procedures as described in Methods.
Expression was normalized to the DDCt value for MCF-7 cells,
with b actin used as an internal control. Data is expressed as a fold
change from MCF7 which was arbitrarily fixed at 100. Histobars
represent means of duplicate determinations. Similar results were
observed in two separate experiments.
(TIF)
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